cepharanthine has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Ding, X; Gao, N; Gong, QH; Jia, GF; Jiang, XX; Lei, L; Li, J; Li, ZQ; Shen, LW; Wang, M | 1 |
1 other study(ies) available for cepharanthine and ER-Negative PR-Negative HER2-Negative Breast Cancer
Article | Year |
---|---|
Cepharanthine sensitizes human triple negative breast cancer cells to chemotherapeutic agent epirubicin via inducing cofilin oxidation-mediated mitochondrial fission and apoptosis.
Topics: Actin Depolymerizing Factors; Antineoplastic Agents; Apoptosis; Benzylisoquinolines; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Epirubicin; Humans; Mitochondrial Dynamics; Molecular Structure; Oxidation-Reduction; Structure-Activity Relationship; Triple Negative Breast Neoplasms; Tumor Cells, Cultured | 2022 |